| Document Date: 2014-10-09 15:26:45
Open Document File Size: 25,37 KBShare Result on Facebook
City New York / Paris / / Company Sanofi / ACS / Genzyme / Sanofi-Aventis / / Country France / / Currency USD / EUR / / Event FDA Phase / Company Listing Change / / IndustryTerm therapeutic solutions / consumer healthcare / healthcare / diabetes solutions / / MedicalCondition NSCLC / platinum-resistant ovarian cancer / squamous non-small cell lung cancer / diabetes / acute coronary syndrome / coronary syndrome / heart attacks / heart attack / / MedicalTreatment chemotherapy / intravenous infusion / / MusicAlbum Day 1 / / Position integrated global healthcare leader / / Product carboplatin / TAO / Xa / Iniparib In / Two Investigational Compounds / investigational / Otamixaban This / / Technology chemotherapy / therapeutic solutions / /
SocialTag |
PRESS RELEASE Sanofi Provides Update on Phase 3 Studies of Two Investigational Compounds Paris, France - June 3, [removed]Sanofi (EURONEXT: SAN and NYSE: SNY) today announced topline results of two Phase 3 clinical studie